BioVie Inc. (BIVI) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by BioVie Inc. on September 11, 2026. The filing discloses the entry into a material definitive agreement to raise capital through an "at-the-market" equity offering.
Key Financial Metrics and Transaction Details
- Transaction Type: Sales Agreement for Class A Common Stock.
- Maximum Offering Amount: Up to $6,464,341 in aggregate offering price.
- Agent: A.G.P./Alliance Global Partners.
- Commission: 3.0% of gross proceeds from shares sold.
- Use of Proceeds: General corporate purposes.
- Financial Performance: The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Outlook
The primary material change is the authorization of a new equity financing mechanism. The Company has no obligation to sell any shares and may suspend or terminate the agreement at any time. The offering will terminate upon the sale of all shares, the expiration of the underlying Registration Statement (June 29, 2029), or earlier termination.
Risks and Contingencies: The sale of shares is subject to market conditions and the Agent's discretion. The filing explicitly states it does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the current market price of BIVI Class A Common Stock to estimate the potential dilution from the $6.46 million offering.
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific termination rights and expense reimbursement details.
- Confirm the status of the underlying Form S-3 Registration Statement (File No. 333-296924) to ensure it remains effective.
- Assess the Company's current cash position and burn rate to determine the urgency of this capital raise.